<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00331344</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2009-00155</org_study_id>
    <secondary_id>055513</secondary_id>
    <secondary_id>CDR0000481121</secondary_id>
    <secondary_id>N01CM62202</secondary_id>
    <nct_id>NCT00331344</nct_id>
    <nct_alias>NCT01648374</nct_alias>
  </id_info>
  <brief_title>Treating Patients With Metastatic Prostate Cancer Not Responding to Hormone and Chemotherapy</brief_title>
  <official_title>Phase I/II Trial of Epothilone Analog BMS-247550 (Ixabepilone), Mitoxantrone, and Prednisone in Hormone Refractory Prostate Cancer (HRPC) Patients Previously Treated With Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I/II trial is studying the side effects and best dose of ixabepilone and
      mitoxantrone hydrochloride when given together with prednisone and to see how well they work
      in treating patients with metastatic prostate cancer that did not respond to hormone therapy
      and chemotherapy. Drugs used in chemotherapy, such as ixabepilone, mitoxantrone
      hydrochloride, and prednisone, work in different ways to stop the growth of tumor cells,
      either by killing the cells or by stopping them from dividing. Giving more than one drug
      (combination chemotherapy) may kill more tumor cells
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. Determine the maximum tolerated dose (MTD) and dose-limiting toxicities of the combination
      of ixabepilone, mitoxantrone hydrochloride, and prednisone in patients with
      hormone-refractory metastatic prostate cancer that progressed during or after taxane-based
      chemotherapy. (Phase I) II. Assess the efficacy, as measured by reduction in
      prostate-specific antigen, of this regimen in these patients. (Phase II)

      SECONDARY OBJECTIVES:

      I. Evaluate the overall safety of this regimen as second-line chemotherapy in these patients.

      II. Evaluate the objective response rate in patients treated with this regimen.

      OUTLINE: This is a multicenter, phase I, open label, dose-escalation study of mitoxantrone
      hydrochloride and ixabepilone followed by a phase II study.

      PHASE I: Patients receive mitoxantrone hydrochloride intravenously (IV) over 30 minutes and
      ixabepilone IV over 3 hours on day 1 and oral prednisone twice daily on days 1-21. Treatment
      repeats every 21 days for ≥ 3 courses in the absence of disease progression or unacceptable
      toxicity. Cohorts of 3-6 patients receive escalating doses of mitoxantrone hydrochloride and
      ixabepilone until the maximum tolerated dose (MTD) is determined. The MTD is defined as the
      dose preceding that at which 2 of 6 patients experience dose-limiting toxicity.

      PHASE II: Patients receive mitoxantrone hydrochloride and ixabepilone at the MTD determined
      in phase I and prednisone as in phase I.

      After completion of study treatment, patients are followed every 3 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2006</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion Responding to Treatment With of the Combination of Ixabepilone and Mitoxantrone Hydrochloride With Prednisone in Hormone Refractory Prostate Cancer Patients Who Have Had Prior Taxane Chemotherapy Based Upon a PSA Decline of &gt; 50% (Phase II)</measure>
    <time_frame>Every 3 courses until cancer progression/excessive toxicity or death</time_frame>
    <description>Descriptive statistics will be calculated to characterize the disease and treatment factors including the proportion responding with a 95% confidence interval. If accrual is completed and more than 15 of 58 patients show &gt; 50% Prostate Specific Antigen (PSA) declines after 3 courses, then the null hypothesis of a 20% response proportion will be rejected. PSA declines for individual patients will be plotted in the form of a waterfall diagram of maximal PSA declines.
58 patients were enrolled for phase II, two were ineligible so 56 patients were analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety of the Combination of Ixabepilone, Mitoxantrone Hydrochloride, and Prednisone in Patients With Hormone-refractory Metastatic Prostate Cancer That Progressed During or After Taxane-based Chemotherapy (Phase I)</measure>
    <time_frame>Every 21 days until cancer progression/excessive toxicity or death</time_frame>
    <description>This study will utilize the Common Terminology Criteria for Adverse Events (CTCAE) v3.0 for adverse event monitoring and reporting. The cumulative grade 3 or higher adverse events for all dose levels are noted below and in the table of adverse events.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose Limiting Toxicities for Each Dose Level of Ixabepilone, Mitoxantrone Hydrochloride, and Prednisone in Patients With Hormone-refractory Metastatic Prostate Cancer That Progressed During or After Taxane-based Chemotherapy (Phase I).</measure>
    <time_frame>Course 1 (first 21 days)</time_frame>
    <description>Cohorts of 3 patients will be enrolled at each dose level; if 1 dose limiting toxicity (DLT) is observed then the cohort will be expanded to 6 patients. If a second DLT is observed, the previous dose level will be considered the maximum tolerated dose (MTD). If all observed DLT are due to neuropathy (specific to ixabepilone), then we would consider the previous dose level of Ixabepilone the MTD for that drug, and escalate mitoxantrone hydrochloride as described above to a maximum dose of 12 mg/m^2. Toxicities will be tabulated by grade for each dose cohort and overall for all patients accrued to the phase I study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Progression (Phase II)</measure>
    <time_frame>Every 3 months until cancer progression/excessive toxicity or death</time_frame>
    <description>Measured from the start of protocol therapy until RECIST (Response Evaluation Criteria In Solid Tumors Criteria) v1.0 progression. Progression is defined as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Adenocarcinoma of the Prostate</condition>
  <condition>Recurrent Prostate Cancer</condition>
  <condition>Stage IV Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment (combination chemotherapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive mitoxantrone hydrochloride IV over 30 minutes and ixabepilone IV over 3 hours on day 1 and oral prednisone twice daily on days 1-21. Treatment repeats every 21 days for ≥ 3 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mitoxantrone hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (combination chemotherapy)</arm_group_label>
    <other_name>CL 232315</other_name>
    <other_name>DHAD</other_name>
    <other_name>DHAQ</other_name>
    <other_name>Novantrone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ixabepilone</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (combination chemotherapy)</arm_group_label>
    <other_name>BMS-247550</other_name>
    <other_name>epothilone B lactam</other_name>
    <other_name>Ixempra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisone</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Treatment (combination chemotherapy)</arm_group_label>
    <other_name>DeCortin</other_name>
    <other_name>Deltra</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed adenocarcinoma of the prostate

          -  Progressive metastatic disease (i.e., positive bone scan or measurable disease)
             despite castrate levels of testosterone (either from orchiectomy or luteinizing
             hormone-releasing hormone [LHRH] agonist therapy)

               -  Progressive disease after discontinuing hormonal therapy

               -  Progressive disease is based on any of the following*:

                    -  Transaxial imaging

                    -  Rise in prostate-specific antigen (PSA)

                    -  Radionuclide bone scan (must show new metastatic lesions)

          -  Nonmeasurable or measurable disease

               -  For measurable disease, progression is defined by RECIST criteria

               -  Positive bone scan and elevated PSA required for nonmeasurable disease

                    -  PSA evidence of progressive prostate cancer during or after first-line
                       chemotherapy consists of a PSA level ≥ 2 ng/mL that has risen on ≥ 2
                       successive occasions ≥ 1 week apart

          -  Received ≥ 3 prior courses of paclitaxel- or docetaxel-based therapy, with disease
             progression documented during therapy or after cessation of therapy

               -  No more than 1 prior chemotherapy regimen

               -  Re-treatment with the same taxane-based regimen allowed

               -  Changes in prior chemotherapy regimen (addition of other agents) for disease
                  progression are considered 2 chemotherapy regimens, and are not allowed

          -  PSA ≥ 2 ng/mL

          -  Testosterone &lt; 50 ng/dL

               -  Patients must continue primary androgen deprivation with LHRH analogue if they
                  have not undergone orchiectomy

          -  No known active brain metastases

          -  ECOG performance status 0-2

          -  Life expectancy ≥ 12 weeks

          -  Creatinine ≤ 1.5 times upper limit of normal (ULN) OR creatinine clearance &gt; 40 mL/min

          -  ALT and AST &lt; 2.5 times ULN

          -  Granulocyte count ≥ 2,000/mm³

          -  Platelet count ≥ 100,000/mm³

          -  Bilirubin &lt; 1.5 times ULN

          -  Ejection fraction normal by MUGA scan or echocardiogram

          -  No significant cardiovascular disease, including any of the following:

               -  Congestive heart failure (New York Heart Association class III-IV heart disease)

               -  Active angina pectoris

               -  Myocardial infarction within the past 6 months

          -  No serious infections or nonmalignant medical illnesses that are uncontrolled or whose
             control may be jeopardized by study therapy

          -  No psychiatric illness or social situation that would preclude study compliance

          -  No pre-existing motor or sensory peripheral neuropathy &gt; grade 1

          -  No known prior severe hypersensitivity reactions to agents containing Cremophor® EL

          -  No &quot;currently active&quot; second malignancy other than nonmelanoma skin cancer

               -  Patients are not considered to have a &quot;currently active&quot; malignancy if they have
                  completed therapy and are considered to be at &lt; 30% risk of relapse

          -  Fertile patients must use effective contraception prior to, during, and for 3 months
             after completion of study treatment

          -  See Disease Characteristics

          -  No prior mitoxantrone hydrochloride, ixabepilone, or other epothilones

          -  At least 4 weeks since prior hormonal therapy (i.e., any dose of megestrol,
             finasteride, or any herbal product known to decrease PSA levels [e.g., saw palmetto or
             PC-SPES]) other than LHRH agonist or a stable dose of corticosteroids from a prior
             chemotherapy regimen

          -  More than 4 weeks since other prior systemic therapies for prostate cancer

          -  At least 4 weeks since prior radiation therapy

          -  More than 8 weeks since prior radiopharmaceuticals (e.g., strontium chloride Sr 89 or
             samarium Sm 153 lexidronam pentasodium)

          -  No concurrent moderate to strong CYP3A4 inhibitors

          -  No concurrent prophylactic colony-stimulating factors

          -  No concurrent radiotherapy
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrea Harzstark</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California San Francisco Medical Center-Mount Zion</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSF Helen Diller Family Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143-0875</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Hospital and Clinics</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Rosenberg JE, Ryan CJ, Weinberg VK, Smith DC, Hussain M, Beer TM, Ryan CW, Mathew P, Pagliaro LC, Harzstark AL, Sharib J, Small EJ. Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy: a study of the department of defense prostate cancer clinical trials consortium. J Clin Oncol. 2009 Jun 10;27(17):2772-8. doi: 10.1200/JCO.2008.19.8002. Epub 2009 Apr 6.</citation>
    <PMID>19349545</PMID>
  </results_reference>
  <results_reference>
    <citation>Harzstark AL, Rosenberg JE, Weinberg VK, Sharib J, Ryan CJ, Smith DC, Pagliaro LC, Beer TM, Liu G, Small EJ. Ixabepilone, mitoxantrone, and prednisone for metastatic castration-resistant prostate cancer after docetaxel-based therapy: a phase 2 study of the Department Of Defense Prostate Cancer Clinical Trials Consortium. Cancer. 2011 Jun 1;117(11):2419-25. doi: 10.1002/cncr.25810. Epub 2010 Dec 29.</citation>
    <PMID>24048789</PMID>
  </results_reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 30, 2006</study_first_submitted>
  <study_first_submitted_qc>May 30, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 31, 2006</study_first_posted>
  <results_first_submitted>June 2, 2017</results_first_submitted>
  <results_first_submitted_qc>October 2, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">October 31, 2017</results_first_posted>
  <last_update_submitted>October 2, 2017</last_update_submitted>
  <last_update_submitted_qc>October 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Epothilone B</mesh_term>
    <mesh_term>Mitoxantrone</mesh_term>
    <mesh_term>Epothilones</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients (incl. currently followed in these practices, as well as those referred from outside providers) will be screened for interest and eligibility by medical oncologists from UCSF Urologic Oncology Practice CCC, UCSF-VA Medical Cntr, OHSU Cancer Inst., MD Anderson Cancer Cntr, UMich Comprehensive Cancer Cntr and the Portland VA Medical Cntr.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Phase I Group I</title>
          <description>Patients receive mitoxantrone hydrochloride 8mg/m2 IV over 30 minutes and ixabepilone 20mg/m2 IV over 3 hours on day 1 and oral prednisone 5mg twice daily on days 1-21. Treatment repeats every 21 days for ≥ 3 courses in the absence of disease progression or unacceptable toxicity.
mitoxantrone hydrochloride: Given IV
ixabepilone: Given IV
prednisone: Given orally</description>
        </group>
        <group group_id="P2">
          <title>Phase I Group II</title>
          <description>Patients receive mitoxantrone hydrochloride 8mg/m2 IV over 30 minutes and ixabepilone 25mg/m2 IV over 3 hours on day 1 and oral prednisone 5mg twice daily on days 1-21. Treatment repeats every 21 days for ≥ 3 courses in the absence of disease progression or unacceptable toxicity.
mitoxantrone hydrochloride: Given IV
ixabepilone: Given IV
prednisone: Given orally</description>
        </group>
        <group group_id="P3">
          <title>Phase I Group III</title>
          <description>Patients receive mitoxantrone hydrochloride 10mg/m2 IV over 30 minutes and ixabepilone 25mg/m2 IV over 3 hours on day 1 and oral prednisone 5mg twice daily on days 1-21. Treatment repeats every 21 days for ≥ 3 courses in the absence of disease progression or unacceptable toxicity.
mitoxantrone hydrochloride: Given IV
ixabepilone: Given IV
prednisone: Given orally</description>
        </group>
        <group group_id="P4">
          <title>Phase I Group IV</title>
          <description>Patients receive mitoxantrone hydrochloride 10mg/m2 IV over 30 minutes and ixabepilone 30mg/m2 IV over 3 hours on day 1 and oral prednisone 5mg twice daily on days 1-21. Treatment repeats every 21 days for ≥ 3 courses in the absence of disease progression or unacceptable toxicity.
mitoxantrone hydrochloride: Given IV
ixabepilone: Given IV
prednisone: Given orally</description>
        </group>
        <group group_id="P5">
          <title>Phase I Group V</title>
          <description>Patients receive mitoxantrone hydrochloride 12mg/m2 IV over 30 minutes and ixabepilone 30mg/m2 IV over 3 hours on day 1 and oral prednisone 5mg twice daily on days 1-21. Treatment repeats every 21 days for ≥ 3 courses in the absence of disease progression or unacceptable toxicity.
mitoxantrone hydrochloride: Given IV
ixabepilone: Given IV
prednisone: Given orally</description>
        </group>
        <group group_id="P6">
          <title>Phase I Group VI</title>
          <description>Patients receive mitoxantrone hydrochloride 12mg/m2 IV over 30 minutes and ixabepilone 35mg/m2 IV over 3 hours on day 1 and oral prednisone 5mg twice daily on days 1-21. Treatment repeats every 21 days for ≥ 3 courses in the absence of disease progression or unacceptable toxicity.
mitoxantrone hydrochloride: Given IV
ixabepilone: Given IV
prednisone: Given orally</description>
        </group>
        <group group_id="P7">
          <title>Phase I Group Va</title>
          <description>Patients receive mitoxantrone hydrochloride 12mg/m2 IV over 30 minutes and ixabepilone 30mg/m2 IV over 3 hours on day 1 and pegfilgrastim 6mg SC on day 2 and oral prednisone 5mg twice daily on days 1-21. Treatment repeats every 21 days for ≥ 3 courses in the absence of disease progression or unacceptable toxicity.
mitoxantrone hydrochloride: Given IV
ixabepilone: Given IV
pegfilgrastim: Given SC
prednisone: Given orally</description>
        </group>
        <group group_id="P8">
          <title>Phase I Group VIa</title>
          <description>Patients receive mitoxantrone hydrochloride 12mg/m2 IV over 30 minutes and ixabepilone 35mg/m2 IV over 3 hours on day 1 and pegfilgrastim 6mg SC on day 2 and oral prednisone 5mg twice daily on days 1-21. Treatment repeats every 21 days for ≥ 3 courses in the absence of disease progression or unacceptable toxicity.
mitoxantrone hydrochloride: Given IV
ixabepilone: Given IV
pegfilgrastim: Given SC
prednisone: Given orally</description>
        </group>
        <group group_id="P9">
          <title>Phase II</title>
          <description>Patients receive mitoxantrone hydrochloride 12mg/m2 IV over 30 minutes and ixabepilone 30mg/m2 IV over 3 hours on day 1 and pegfilgrastim 6mg SC on day 2 and oral prednisone 5mg twice daily on days 1-21. Treatment repeats every 21 days for ≥ 3 courses in the absence of disease progression or unacceptable toxicity.
mitoxantrone hydrochloride: Given IV
ixabepilone: Given IV
pegfilgrastim: Given SC
prednisone: Given orally</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Phase I</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="5"/>
                <participants group_id="P7" count="4"/>
                <participants group_id="P8" count="6">1 participant who was enrolled died prior to initiating protocol therapy.</participants>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="5">1 participant reached dose limiting toxicity</participants>
                <participants group_id="P5" count="4">2 participants reached dose limiting toxicity</participants>
                <participants group_id="P6" count="3">2 participants reached dose limiting toxicity</participants>
                <participants group_id="P7" count="4"/>
                <participants group_id="P8" count="5">1 participant reached dose limiting toxicity</participants>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Phase II</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="6">6 patients in Phase I Group VIa continued to the Phase II period.</participants>
                <participants group_id="P9" count="52">Protocol enrollment (63) minus 11 ineligible prior to receiving treatment.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment (Combination Chemotherapy)</title>
          <description>Patients receive mitoxantrone hydrochloride IV over 30 minutes and ixabepilone IV over 3 hours on day 1 and oral prednisone twice daily on days 1-21. Treatment repeats every 21 days for ≥ 3 courses in the absence of disease progression or unacceptable toxicity.
mitoxantrone hydrochloride: Given IV
ixabepilone: Given IV
prednisone: Given orally</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="88"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.7" lower_limit="39" upper_limit="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Proportion Responding to Treatment With of the Combination of Ixabepilone and Mitoxantrone Hydrochloride With Prednisone in Hormone Refractory Prostate Cancer Patients Who Have Had Prior Taxane Chemotherapy Based Upon a PSA Decline of &gt; 50% (Phase II)</title>
        <description>Descriptive statistics will be calculated to characterize the disease and treatment factors including the proportion responding with a 95% confidence interval. If accrual is completed and more than 15 of 58 patients show &gt; 50% Prostate Specific Antigen (PSA) declines after 3 courses, then the null hypothesis of a 20% response proportion will be rejected. PSA declines for individual patients will be plotted in the form of a waterfall diagram of maximal PSA declines.
58 patients were enrolled for phase II, two were ineligible so 56 patients were analyzed.</description>
        <time_frame>Every 3 courses until cancer progression/excessive toxicity or death</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Combination Chemotherapy)</title>
            <description>Patients receive mitoxantrone hydrochloride 12mg/m2 IV over 30 minutes and ixabepilone 35mg/m2 IV over 3 hours on day 1 and pegfilgrastim 6mg SC on day 2 and oral prednisone twice daily on days 1-21. Treatment repeats every 21 days for ≥ 3 courses in the absence of disease progression or unacceptable toxicity.
mitoxantrone hydrochloride: Given IV
ixabepilone: Given IV
pegfilgrastim: Given SC
prednisone: Given orally</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion Responding to Treatment With of the Combination of Ixabepilone and Mitoxantrone Hydrochloride With Prednisone in Hormone Refractory Prostate Cancer Patients Who Have Had Prior Taxane Chemotherapy Based Upon a PSA Decline of &gt; 50% (Phase II)</title>
          <description>Descriptive statistics will be calculated to characterize the disease and treatment factors including the proportion responding with a 95% confidence interval. If accrual is completed and more than 15 of 58 patients show &gt; 50% Prostate Specific Antigen (PSA) declines after 3 courses, then the null hypothesis of a 20% response proportion will be rejected. PSA declines for individual patients will be plotted in the form of a waterfall diagram of maximal PSA declines.
58 patients were enrolled for phase II, two were ineligible so 56 patients were analyzed.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety of the Combination of Ixabepilone, Mitoxantrone Hydrochloride, and Prednisone in Patients With Hormone-refractory Metastatic Prostate Cancer That Progressed During or After Taxane-based Chemotherapy (Phase I)</title>
        <description>This study will utilize the Common Terminology Criteria for Adverse Events (CTCAE) v3.0 for adverse event monitoring and reporting. The cumulative grade 3 or higher adverse events for all dose levels are noted below and in the table of adverse events.</description>
        <time_frame>Every 21 days until cancer progression/excessive toxicity or death</time_frame>
        <population>Phase I dose escalation study participants</population>
        <group_list>
          <group group_id="O1">
            <title>Phase I Treatment (Groups I-VIa)</title>
            <description>Patients receive mitoxantrone hydrochloride 8-12mg/m2 IV over 30 minutes and ixabepilone 20-35mg/m2 IV over 3 hours on day 1 and oral prednisone twice daily on days 1-21. Patients in groups Va and VIa also received pegfilgrastim 6mg SC on day 2. Treatment repeats every 21 days for ≥ 3 courses in the absence of disease progression or unacceptable toxicity.
mitoxantrone hydrochloride: Given IV
ixabepilone: Given IV
pegfilgrastim: Given SC
prednisone: Given orally</description>
          </group>
        </group_list>
        <measure>
          <title>Safety of the Combination of Ixabepilone, Mitoxantrone Hydrochloride, and Prednisone in Patients With Hormone-refractory Metastatic Prostate Cancer That Progressed During or After Taxane-based Chemotherapy (Phase I)</title>
          <description>This study will utilize the Common Terminology Criteria for Adverse Events (CTCAE) v3.0 for adverse event monitoring and reporting. The cumulative grade 3 or higher adverse events for all dose levels are noted below and in the table of adverse events.</description>
          <population>Phase I dose escalation study participants</population>
          <units>Adverse Events (above threshold)</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Dose Limiting Toxicities for Each Dose Level of Ixabepilone, Mitoxantrone Hydrochloride, and Prednisone in Patients With Hormone-refractory Metastatic Prostate Cancer That Progressed During or After Taxane-based Chemotherapy (Phase I).</title>
        <description>Cohorts of 3 patients will be enrolled at each dose level; if 1 dose limiting toxicity (DLT) is observed then the cohort will be expanded to 6 patients. If a second DLT is observed, the previous dose level will be considered the maximum tolerated dose (MTD). If all observed DLT are due to neuropathy (specific to ixabepilone), then we would consider the previous dose level of Ixabepilone the MTD for that drug, and escalate mitoxantrone hydrochloride as described above to a maximum dose of 12 mg/m^2. Toxicities will be tabulated by grade for each dose cohort and overall for all patients accrued to the phase I study.</description>
        <time_frame>Course 1 (first 21 days)</time_frame>
        <population>Dose escalation safety study (Phase I)</population>
        <group_list>
          <group group_id="O1">
            <title>Phase I Group I</title>
            <description>Patients receive mitoxantrone hydrochloride 8 mg/m2 IV over 30 minutes and ixabepilone 20mg/m2 IV over 3 hours on day 1 and oral prednisone twice daily on days 1-21. Treatment repeats every 21 days for ≥ 3 courses in the absence of disease progression or unacceptable toxicity.
mitoxantrone hydrochloride: Given IV
ixabepilone: Given IV
prednisone: Given orally</description>
          </group>
          <group group_id="O2">
            <title>Phase Group II</title>
            <description>Patients receive mitoxantrone hydrochloride 8 mg/m2 IV over 30 minutes and ixabepilone 25mg/m2 IV over 3 hours on day 1 and oral prednisone twice daily on days 1-21. Treatment repeats every 21 days for ≥ 3 courses in the absence of disease progression or unacceptable toxicity.
mitoxantrone hydrochloride: Given IV
ixabepilone: Given IV
prednisone: Given orally</description>
          </group>
          <group group_id="O3">
            <title>Phase I Group III</title>
            <description>Patients receive mitoxantrone hydrochloride 10 mg/m2 IV over 30 minutes and ixabepilone 25 mg/m2 IV over 3 hours on day 1 and oral prednisone twice daily on days 1-21. Treatment repeats every 21 days for ≥ 3 courses in the absence of disease progression or unacceptable toxicity.
mitoxantrone hydrochloride: Given IV
ixabepilone: Given IV
prednisone: Given orally</description>
          </group>
          <group group_id="O4">
            <title>Phase I Group IV</title>
            <description>Patients receive mitoxantrone hydrochloride 10 mg/m2 IV over 30 minutes and ixabepilone 30mg/m2 IV over 3 hours on day 1 and oral prednisone twice daily on days 1-21. Treatment repeats every 21 days for ≥ 3 courses in the absence of disease progression or unacceptable toxicity.
mitoxantrone hydrochloride: Given IV
ixabepilone: Given IV
prednisone: Given orally</description>
          </group>
          <group group_id="O5">
            <title>Phase I Group V</title>
            <description>Patients receive mitoxantrone hydrochloride 12 mg/m2 IV over 30 minutes and ixabepilone 30mg/m2 IV over 3 hours on day 1 and oral prednisone twice daily on days 1-21. Treatment repeats every 21 days for ≥ 3 courses in the absence of disease progression or unacceptable toxicity.
mitoxantrone hydrochloride: Given IV
ixabepilone: Given IV
prednisone: Given orally</description>
          </group>
          <group group_id="O6">
            <title>Phase I Group VI</title>
            <description>Patients receive mitoxantrone hydrochloride 12 mg/m2 IV over 30 minutes and ixabepilone 35mg/m2 IV over 3 hours on day 1 and oral prednisone twice daily on days 1-21. Treatment repeats every 21 days for ≥ 3 courses in the absence of disease progression or unacceptable toxicity.
mitoxantrone hydrochloride: Given IV
ixabepilone: Given IV
prednisone: Given orally</description>
          </group>
          <group group_id="O7">
            <title>Phase I Group Va</title>
            <description>Patients receive mitoxantrone hydrochloride 12 mg/m2 IV over 30 minutes and ixabepilone 30mg/m2 IV over 3 hours on day 1 and pegfilgrastim 6mg SC on day 2 and oral prednisone twice daily on days 1-21. Treatment repeats every 21 days for ≥ 3 courses in the absence of disease progression or unacceptable toxicity.
mitoxantrone hydrochloride: Given IV
ixabepilone: Given IV
pegfilgrastim: Given SC
prednisone: Given orally</description>
          </group>
          <group group_id="O8">
            <title>Phase I Group VIa</title>
            <description>Patients receive mitoxantrone hydrochloride 12 mg/m2 IV over 30 minutes and ixabepilone 35mg/m2 IV over 3 hours on day 1 and pegfilgrastim 6mg SC on day 2 and oral prednisone twice daily on days 1-21. Treatment repeats every 21 days for ≥ 3 courses in the absence of disease progression or unacceptable toxicity.
mitoxantrone hydrochloride: Given IV
ixabepilone: Given IV
pegfilgrastim: Given SC
prednisone: Given orally</description>
          </group>
        </group_list>
        <measure>
          <title>Dose Limiting Toxicities for Each Dose Level of Ixabepilone, Mitoxantrone Hydrochloride, and Prednisone in Patients With Hormone-refractory Metastatic Prostate Cancer That Progressed During or After Taxane-based Chemotherapy (Phase I).</title>
          <description>Cohorts of 3 patients will be enrolled at each dose level; if 1 dose limiting toxicity (DLT) is observed then the cohort will be expanded to 6 patients. If a second DLT is observed, the previous dose level will be considered the maximum tolerated dose (MTD). If all observed DLT are due to neuropathy (specific to ixabepilone), then we would consider the previous dose level of Ixabepilone the MTD for that drug, and escalate mitoxantrone hydrochloride as described above to a maximum dose of 12 mg/m^2. Toxicities will be tabulated by grade for each dose cohort and overall for all patients accrued to the phase I study.</description>
          <population>Dose escalation safety study (Phase I)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>Cohorts of 3 patients will be enrolled at each dose level; if 1 dose limiting toxicity (DLT) is observed then the cohort will be expanded to 6 patients. If a second DLT is observed, the previous dose level will be considered the MTD. If all observed DLT are due to neuropathy (specific to ixabepilone), then we would consider the previous dose level of Ixabepilone the MTD for that drug, and escalate mitoxantrone hydrochloride as described above to a maximum dose of 12 mg/m^2.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Dose Level VIa</param_type>
            <param_value>1</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Dose level VIa (mitoxantrone hydrochloride 12 mg/m2 IV over 30 minutes, ixabepilone 30mg/m2 IV over 3 hours on day 1, pegfilgrastim 6mg SC on day 2, oral prednisone twice daily on days 1-21) was determined to be MTD, based on 1 event of DLT at VIa.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Progression (Phase II)</title>
        <description>Measured from the start of protocol therapy until RECIST (Response Evaluation Criteria In Solid Tumors Criteria) v1.0 progression. Progression is defined as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.</description>
        <time_frame>Every 3 months until cancer progression/excessive toxicity or death</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Combination Chemotherapy)</title>
            <description>Patients receive mitoxantrone hydrochloride 12mg/m2 IV over 30 minutes and ixabepilone 35mg/m2 IV over 3 hours on day 1 and pegfilgrastim 6mg SC on day 2 and oral prednisone twice daily on days 1-21. Treatment repeats every 21 days for ≥ 3 courses in the absence of disease progression or unacceptable toxicity.
mitoxantrone hydrochloride: Given IV
ixabepilone: Given IV
pegfilgrastim: Given SC
prednisone: Given orally</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Progression (Phase II)</title>
          <description>Measured from the start of protocol therapy until RECIST (Response Evaluation Criteria In Solid Tumors Criteria) v1.0 progression. Progression is defined as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" lower_limit="3.5" upper_limit="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Phase I and Phase II (Cumulative)</title>
          <description>Patients in the Phase I period receive mitoxantrone hydrochloride 8-12mg/m2 IV over 30 minutes and ixabepilone 20-35mg/m2 IV over 3 hours on day 1 and oral prednisone twice daily on days 1-21. Patients in groups Va and VIa also received pegfilgrastim 6mg SC on day 2. Treatment repeats every 21 days for ≥ 3 courses in the absence of disease progression or unacceptable toxicity.
Patients in Phase II receive mitoxantrone hydrochloride 12mg/m2 IV over 30 minutes and ixabepilone 35mg/m2 IV over 3 hours on day 1 and pegfilgrastim 6mg SC on day 2 and oral prednisone twice daily on days 1-21. Treatment repeats every 21 days for ≥ 3 courses in the absence of disease progression or unacceptable toxicity.
Adverse Events below are reported cumulatively for the entire study.
mitoxantrone hydrochloride: Given IV
ixabepilone: Given IV
pegfilgrastim: Given SC
prednisone: Given orally</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE v3.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leucocytes</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Febrile Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Cardiac ischemia/infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Vasovagal episode</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Adrenal Insuffiency</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Glucose intolerance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection (limb)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Methicillin-resistant Staphylococcus aureus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Infection (Prostate)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep Vein Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE v3.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Leucocytes</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Edema, limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Adrenal insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Hot Flashes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Pain, other</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Pain, hip</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Weight Loss</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic Reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection, Colon</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Infection, Skin</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain, bone</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Muscle Weakness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Peripheral Motor Neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Taste Alteration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pain, Chest</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Acute Respiratory Distress Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Andrea Harzstark, M.D.</name_or_title>
      <organization>Oakland Medical Center</organization>
      <phone>510-752-6789</phone>
      <email>andrea.l.harzstark@kp.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

